Metabolic Liver Disease Projected to Affect 1.8 Billion People Worldwide by 2050
Metabolic liver disease is on track to become a global health crisis of unprecedented scale, with new research projecting it will affect approximately 1.8 billion people worldwide by 2050. The startling findings, published in the Lancet Gastroenterology & Hepatology journal, reveal that metabolic dysfunction-associated steatotic liver disease (MASLD) – previously known as non-alcoholic fatty liver disease (NAFLD) – has already experienced explosive growth over the past three decades.
Explosive Growth in Metabolic Liver Disease Cases
The comprehensive global burden of diseases study reveals that MASLD cases have skyrocketed by 143% in just three decades. From approximately 500 million affected individuals in 1990, the number has surged to 1.3 billion people worldwide currently living with the condition. This represents about one in six people globally, or 16% of the world's population.
The global prevalence rate has climbed dramatically to 14,429 cases per 100,000 people in 2023, marking a 29% increase since 1990. Researchers project this alarming trend will continue, with MASLD expected to affect 1.8 billion people by 2050 – representing a further 42% rise from current levels.
Key Drivers and Demographic Patterns
The study identifies three primary factors driving MASLD-related health problems worldwide. High blood sugar emerged as the leading contributor, followed closely by high body mass index (BMI) and smoking. These findings highlight the strong connections between metabolic liver disease, type 2 diabetes, and obesity.
MASLD demonstrates distinct demographic patterns, being more common in men than women and showing the highest prevalence rates among older adults aged 80 to 84. However, the largest number of affected individuals are surprisingly younger – around 35 to 39 years old in men and 55 to 59 in women.
Regional Variations and National Trends
Certain regions face disproportionately higher rates of MASLD compared to others. North Africa and the Middle East show particularly elevated prevalence, though sharp increases have been documented across countries worldwide.
In the United Kingdom, the prevalence rate increased by a substantial 33% between 1990 and 2023 – the most significant rise observed in Western Europe. Australia experienced a 30% increase during the same period, while the United States saw a 22% rise in metabolic liver disease cases.
Health Impact and Treatment Considerations
Despite the dramatic increase in case numbers, the study found that the overall health impact – measured in years lost due to illness or death – has remained relatively stable. This suggests that advances in treatment and medical care are helping people live longer and healthier lives with the condition, and that many new cases are being detected in earlier, less severe stages.
Nevertheless, the growing number of cases means millions remain at risk of developing serious complications such as liver cirrhosis or cancer in the future. MASLD is frequently linked to being overweight and can typically be managed through lifestyle modifications.
Silent Nature and Detection Challenges
Metabolic liver disease often presents without noticeable symptoms, meaning many individuals have the condition without realizing it. According to the NHS in England, MASLD is usually discovered incidentally when patients undergo tests for unrelated reasons.
When symptoms do occur, they may include persistent fatigue, general malaise, and liver pain or discomfort felt in the abdomen under the right side of the ribs. The silent progression of the disease underscores the importance of regular health screenings, particularly for individuals with risk factors such as obesity or diabetes.
Research Implications and Public Health Response
The study, led by the Institute for Health Metrics and Evaluation at the University of Washington in Seattle, emphasizes that MASLD is increasingly affecting younger adults amid worsening global health trends and lifestyle factors.
Researchers stress that the dramatic rise in metabolic liver disease cases underscores the urgent need to recognize it as a global health priority. They call for the development of comprehensive policies, targeted awareness campaigns, and effective interventions to mitigate its growing impact and prevent future complications on a worldwide scale.
